Abstract
Bernard–Soulier syndrome (BSS) is a rare congenital platelet disorder characterized by defective platelet adhesion and manifested by spontaneous and often profuse bleeding. Recombinant factor VIIa (rFVIIa) is a haemostatic agent licensed for the treatment of bleeding episodes in patients with haemophilia and inhibitors, which may represent a low-risk alternative to existing therapies in the management of patients with BSS. Here, we describe the use of rFVIIa for the treatment of three severe bleeding episodes in two patients with BSS. Data were extracted by automated searching of the international, Internet-based registry http://www.haemostasis.com. Patient 1, a 24-year-old woman, was admitted with severe epistaxis and hypotension. The diagnosis of BSS was confirmed by macrothrombocytopenia, absence of ristocetin-induced platelet agglutination (RIPA) and absence of glycoprotein (GP) Ibα and IX on the platelet surface. Epsilon aminocaproic acid (EACA; two 50-mg/kg doses), packed red blood cells (PRBCs, 2 U) and platelets (30 U) failed to control the bleeding and, after 13 h, three bolus doses of rFVIIa (90 μg/kg body weight) and a third dose of EACA were administered; bleeding stopped after the third dose of rFVIIa. Patient 2, a 15-year-old girl, initially presented with severe menorrhagia. A lack of RIPA and severe deficiency of GPIbα on the platelet surface confirmed the diagnosis of BSS. EACA and fresh-frozen plasma did not control the haemorrhage, but two bolus doses of rFVIIa (98 μg/kg body weight) resulted in a marked decrease in bleeding. On second admission, patient 2 had severe epistaxis and mild menorrhagia. Two rFVIIa doses (98 and 122.5 μg/kg body weight) were given, and the bleeding stopped. No adverse events were reported in these cases. These three admissions highlight the potential of rFVIIa for the treatment of severe bleeds in patients with BSS.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00277-005-1080-y/MediaObjects/277_2005_1080_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00277-005-1080-y/MediaObjects/277_2005_1080_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00277-005-1080-y/MediaObjects/277_2005_1080_Fig3_HTML.gif)
Similar content being viewed by others
References
Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899–909
Aldouri M (2002) The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 32(Suppl 1):41–46
Almeida AM, Khair K, Hann I, Liesner R (2003) The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121:477–481
Balduini CL, Iolascon A, Savoia A (2002) Inherited thrombocytopenias: from genes to therapy. Haematologica 87:860–880
Berndt MC, Fournier DJ, Castaldi PA (1989) Bernard–Soulier syndrome. Baillieres Clin Haematol 2:585–607
Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP (2003) Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol 101:1174–1176
Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F (1996) Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against von Willebrand factor. Haemostasis 26(Suppl 1):150–154
d’Oiron R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Negrier C (2000) Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 83:644–647
De Marco L, Mazzucato M, Masotti A, Fenton JW, Ruggeri ZM (1991) Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chem 266:23776–23783
Dunlop LC, Andrews RK, Berndt MC (1994) Congenital disorders of platelet function. In: Loscalzo J, Schafer AI (eds) Thrombosis and hemorrhage. Blackwell Scientific, Boston, p 615
Dutton RP, Hess JR, Scalea TM (2003) Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 15:184–188
Grossman RE, Geisen U, Schwender S, Keller F (2000) Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with Type III von Willebrand’s disease and alloantibodies against von Willebrand factor. Thromb Haemost 83:633–634
Hoffman M, Monroe DM (2001) A cell-based model of hemostasis. Thromb Haemost 85:958–965
Hunault M, Bauer KA (2000) Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost 26:401–405
Kaleelrahman M, Minford A, Parapia LA (2004) Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 125:95–96
Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879
Kenny D, Jonsson OG, Morateck PA, Montgomery RR (1998) Naturally occurring mutations in glycoprotein Ibalpha that result in defective ligand binding and synthesis of a truncated protein. Blood 92:175–183
Kenny D, Morateck PA, Gill JC, Montgomery RR (1999) The critical interaction of glycoprotein (GP) IBbeta with GPIX—a genetic cause of Bernard–Soulier syndrome. Blood 93:2968–2975
Kessler C (2004) Haemostasis.com: clinical experiences in the investigational use of rFVIIa in the management of severe haemorrhage. Br J Haematol 127:230
Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U (1996) Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 26(Suppl 1):159–164
Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR (1999) Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354:1940–1947
Locatelli F, Rossi G, Balduini C (2003) Hematopoietic stem-cell transplantation for the Bernard–Soulier syndrome. Ann Intern Med 138:79
Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC (1998) Bernard–Soulier syndrome. Blood 91:4397–4418
Margaglione M, D’Andrea G, Grandone E, Brancaccio V, Amoriello A, Di Minno G (1999) Compound heterozygosity (554–589 del, C515-T transition) in the platelet glycoprotein Ib alpha gene in a patient with a severe bleeding tendency. Thromb Haemost 81:486–492
Mariani G, Testa MG, Di Paolantonio T, Molskov BR, Hedner U (1999) Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 77:131–136
Martinowitz U, Kenet G, Lubetsky A, Segal E (2002) Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 49:S15–S20
Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M (2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51:431–439
Meijer K, Peters FT, van der Meer J (2001) Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand’s disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis 12:211–213
Monroe DM, Roberts HR (2003) Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 23:8–9
Moran N, Morateck PA, Deering A, Ryan M, Montgomery RR, Fitzgerald DJ, Kenny D (2000) Surface expression of glycoprotein Ib alpha is dependent on glycoprotein Ib beta: evidence from a novel mutation causing Bernard–Soulier syndrome. Blood 96:532–539
Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, Aznar I, Carceller S, Sanz MA (2001) Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 114:174–176
Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM (2003) Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 50:599–602
Peters M, Heijboer H (1998) Treatment of a patient with Bernard–Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 80:352
Poon MC, d’Oiron R (2000) Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International registry on recombinant factor VIIa and congenital platelet disorders group. Blood Coagul Fibrinolysis 11(Suppl 1):S55–S68
Poon MC, Demers C, Jobin F, Wu JW (1999) Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94:3951–3953
Seremetis S (2003) Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis 14(Suppl 1):S29–S30
Sobieszczyk S, Breborowicz GH, Markwitz W, Mallinger S, Adamski D, Kruszynski Z (2002) Effect of recombinant activated factor VII (RFVIIA; NovoSeven) in a patient in haemorrhagic shock after obstetrical hysterectomy. Ginekol Pol 73:230–233
Tanaka KA, Waly AA, Cooper WA, Levy JH (2003) Treatment of excessive bleeding in Jehovah’s Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 98:1513–1515
van Buuren HR, Wielenga JJ (2002) Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann’s thrombasthenia. Dig Dis Sci 47:2134–2136
Waldenstrom E, Holmberg L, Axelsson U, Winqvist I, Nilsson IM (1991) Bernard–Soulier syndrome in two Swedish families: effect of DDAVP on bleeding time. Eur J Haematol 46:182–187
Zupancic SS, Sokolic V, Viskovic T, Sanjug J, Simic M, Kastelan M (2002) Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol 108:162–163
Acknowledgements
All the case records in this paper are taken from the international peer-reviewed, Internet-based registry, http://www.haemostasis.com. This registry is supported by an unrestricted educational grant from Novo Nordisk. The authors would like to thank Jørgen Ingerslev for his expert opinion in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozelo, M.C., Svirin, P. & Larina, L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard–Soulier syndrome. Ann Hematol 84, 816–822 (2005). https://doi.org/10.1007/s00277-005-1080-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-1080-y